TSRA-196

DRUG2 trials

Sponsors

Tessera Therapeutics Inc., Tessera Therapeutics, Inc.

Conditions

Alpha-1 Antitrypsin Deficiency (AATD)Lung and/or Liver Disease Associated with Alpha-1 Antitrypsin Deficiency (AATD)

Phase 1

A Study of TSRA-196 in Adults With PiZZ Alpha-1 Antitrypsin Deficiency (AATD)

RecruitingNCT07227207

Tessera Therapeutics, Inc.Alpha-1 Antitrypsin Deficiency (AATD)

Start: 2026-04-21End: 2029-03-01Target: 72Updated: 2026-09-03

TSRA196-AAT-201: A Phase 1/2, Open-Label, Multi-Center, Dose Escalation, Dose Expansion, and Single Repeat Dose Study of TSRA-196 in Adults With the PiZZ Genotype Who Have Lung and/or Liver Disease Associated with Severe Alpha-1 Antitrypsin Deficiency

Not yet recruitingCTIS2025-523497-16-00

Tessera Therapeutics Inc.Lung and/or Liver Disease Associated with Alpha-1 Antitrypsin Deficiency (AATD)

Target: 10Updated: 2026-06-08